LIST OF FIGURES

Figure No.	Title	Page No.
Fig. 2.1.	General structure of SLN.	10
Fig 2.2	Creation and stabilization of nanoparticles, from the perspective of surface energetics.	30
Fig 2.3	Potential energy curve for approach of two nanoparticles.	32
Fig 2.4:	Schematic of the two general nanoparticles production techniques	33
Fig 2.5.	Principle of pearl mill type; pearls are moved by the stirrer.	35
Figure 2.6	Solubility Cs of RMKP 22 microparticles (MP) with a mean diameter of 2400 nm and of two RMKP 22 nanosuspensions with diameters of 800 and 300 nm (Ns-800, Ns-300). (Modified from Ref. Muller R. H. 1996).	47
Figure 2.7	Electron micrograph of prednisolone nanosuspension (Muller R.H.1996).	48
Fig .3.1	Calibration Curve of SQ in Methanol	98
Fig. 3.2	Calibration Curve of SQ in Water	99
Fig.3.3	Calibration Curve of SQ in 0.1 N HCl	100
Fig. 3.4	Calibration Curve of SQ in pH 4.5 Buffer	101
Fig. 3.5	Calibration curve of SQ in pH 7.2 Buffer	102
Fig. 3.6	Calibration Curve of ADF in water	103
Fig. 3.7	Calibration Curve of ADF in IPA	107
Fig. 3.8	Calibration Curve of ADF in DCM: IPA	108
Fig. 3.9	Calibration Curve of ADF in 0.1 N HCl	109
Fig. 3.10	Calibration Curve of ADF in pH 4.5 Buffer	110
Fig. 3.11	Calibration curve of ADF in pH 7.2 Phosphate Buffer	111
Fig. 4.1.	Effect of emulsifier concentration on mean particle diameter and PDI	124
Fig. 4.2	DSC thermogram of Saquinavir (A), Stearic acid (B), Glyceryl monostearate (C), SQ loaded GMS SLNs (D), SQ loaded lyophilized SLNs -SQSLN (E)	127
Fig. 4.3	X ray diffraction spectra of SQ (A), Stearic acid (B) and SQ loaded SLN (C), sucrose (D)	129
Fig.4.4 A)	TEM image of SQ loaded SA SLN (bar indicates 500 nm); B) TEM image of a single particle (bar indicates 100 nm)	130
Fig. 4.5	In vitro release of SQ from SQSLN	132
Fig. 4.6	In vitro release of SQ from SQMLN	132
Fig. 4.7.	Short term stability study of SQ Stearic acid SLN dispersion stored at	134
Fig. 4.8	SQ SLN dispersion stored at 2 – 8 ^{0}C	135
Fig. 4.9	Saquinavir lyophilized SLNs stored at 2 – 8 ^{0}C	135
Fig. 4.10	Drug content of Saquinavir SLNs dispersion and lyophilized SLNs stored at 2 – 8 ^{0}C	136
Fig. 4.11	Mean Particle diameter and PDI of Saquinavir lyophilized SLNs stored at room temp.	137
Fig. 4.12	Zeta potential and drug content of Saquinavir lyophilized SLNs stored at R.T.	137
Fig 5.1	Particle size distribution of Bulk Saquinavir by Malvern Mastersizer	146
Fig.5.2	Particle size distribution of Saquinavir nanosuspension after 10 hrs	146
Fig. 5.2a:	Response surface plot showing the influence of Volume of milling media and concentration of surfactant on Mean particle diameter on Day 0.	151
Fig 5.2b:	Corresponding contour plot showing the effect of factors on Mean particle diameter - Day 0.	151

Fig. 5.3a:	**Response surface plot showing the influence of Volume of milling media and concentration of surfactant on Mean particle diameter on Day 7.**	153
Fig 5.3b:	**Corresponding contour plot showing the effect of factors on Mean particle diameter - Day 7.**	153
Fig. 5.4	**DSC thermograms of Saquinavir (A) and Saquinavir lyophilized Nanosuspension (B).**	156
Fig. 5.5.	**XRD of Bulk Saquinavir (A) and Saquinavir Nanosuspension (B)**	157
Fig. 5.6	**Optical microscope image of Saquinavir Bulk**	157
Fig 5.7	**TEM image of Saquinavir Nanosuspension (Bar indicates 0.4 µm)**	158
Fig 5.8	**In vitro release of Saquinavir suspension and Saquinavir Nanosuspension in 0.1 N HCl**	159
Fig. 6.1	**Plasma concentration- time curve after oral and I.V. administration of Saquinavir Microsuspension (SMS).**	168
Fig 6.2	**Plasma concentration time profile of SMS, SNS and SQSLN after oral Administration.**	168
Fig 6.3	**Concentration (µg/gm) time profile of ^{99m}Tc labeled SMS, SNS and SQSLN in different organs**	174
Fig 7.1	**Effect of emulsifier concentration on mean particle diameter**	189
Fig. 7.2.	**Effect of drug loading on entrapment efficiency**	190
Fig. 7.3.	**DSC thermograms of, Adefovir (A) Physical mixture (B) and Adefovir loaded SLNs(C)**	191
Fig 7.4	**X ray diffractogram of ADF (A), ADF SLN (B), Physical mixture (C) and Dynasan 114 (D)**	193
Fig 7.5	**TEM image of Adefovir loaded SLNs sample (Bar indicates 500 nm)**	194
Fig. 7.6	**In vitro release of Adefovir loaded SLNs in pH 1.2, PB 4.5 and PB 7.2**	195
Fig. 7.7.	**Short term stability study of SLN dispersion**	196
Fig. 7.8	**Particle Size, PDI & Zeta potential of Adefovir SLNs dispersion stored at 2-8 ^{0}C**	197
Fig. 7.9.	**P. size, PDI and Zeta potential of Adefovir lyophilized SLNs stored at 2 - 8^{0}C**	198
Fig. 7.10.	**Drug content of Adefovir SLN dispersion & Lyophilized SLNs stored at 2- 8^{0}C**	198
Fig. 7.11.	**Mean Particle diameter and PDI of Adefovir lyophilized SLNs stored at room temp**	199
Fig. 7.12.	**Zeta potential & Drug content of Adefovir SLNs lyophilized and stored at room temp**	200
Fig 8.1	**Particle size distribution of Bulk Adefovir by Malvern Mastersizer**	210
Fig. 8.2	**Particle size distribution of Adefovir nanosuspension after 18 hrs of milling**	210
Fig. 8.3a:	**Response surface plot showing the influence of Volume of milling media and concentration of surfactant on Mean particle diameter on Day 0.**	211
Fig 8.3b:	**Corresponding contour plot showing the effect of factors on Mean particle diameter - Day 0.**	215
Fig. 8.4a:	**Response surface plot showing the influence of Volume of milling media and concentration of surfactant on Mean particle diameter on Day 7.**	217
Fig 8.4b:	**Corresponding contour plot showing the effect of factors on Mean particle diameter on Day 7.**	217

Fig. 8.5	**DSC thermograms of ADF (A) and lyophilized Nanosuspension (B).**	221
Fig. 8.6	**X Ray diffractogram of ADF and ARDX**	222
Fig 8.7	**Optical image of Adefovir bulk sample**	223
Fig. 8.8	**TEM image of Adefovir Nanosuspension (Bar indicates 0.4 μm)**	223
Fig. 8.9	**In vitro release ADF from AMS and ANS**	224
Fig 9.1.	**Chromatographic Characterization of ^{99m}Tc ADF Solid Lipid nanoparticles**	229
Fig. 9.2	**Plasma concentration- time curve after oral and I.V. administration of Adefovir Microsuspension (AMS).**	231
Fig 9.3	**Plasma concentration time profile of AMS, ANS and ADSLN after oral administration.**	231
Fig 9.4	**Concentration time profile of ^{99m}Tc labeled AMS, ANS and ADSLN in different organs**	232